Publication: Comparative Studies of Resveratrol, Oxyresveratrol and Dihydrooxyresveratrol on Doxorubicin-Treated Lung Cancer Cells
3
0
Issued Date
2024-01-01
Resource Type
ISSN
15137368
eISSN
2476762X
Scopus ID
2-s2.0-85189272511
Pubmed ID
38546076
Journal Title
Asian Pacific Journal of Cancer Prevention
Volume
25
Issue
3
Start Page
939
End Page
949
Rights Holder(s)
SCOPUS
Bibliographic Citation
Asian Pacific Journal of Cancer Prevention Vol.25 No.3 (2024) , 939-949
Suggested Citation
Yahayo W., Pongkittiphan V., Supabphol R., Saiyudthong S. Comparative Studies of Resveratrol, Oxyresveratrol and Dihydrooxyresveratrol on Doxorubicin-Treated Lung Cancer Cells. Asian Pacific Journal of Cancer Prevention Vol.25 No.3 (2024) , 939-949. 949. doi:10.31557/APJCP.2024.25.3.939 Retrieved from: https://hdl.handle.net/20.500.14740/20062
Author(s)
Corresponding Author(s)
Other Contributor(s)
Abstract
Objectives: This research aims to comparatively investigate the capability of resveratrol (RES) and RES analogues, oxyresveratrol (Oxy-RES) and dihydrooxyresveratrol (DHoxy-RES), to potentiate doxorubicin (DOX) effects against lung carcinoma epithelial cells. Methods: All experiments were performed on lung carcinoma cell lines (A549) with DOX combination between DOX and RES or RES analogues. Cell viability or growth inhibitory effect was assessed by MTT assay and genes associated with survival and metastasis were monitored by real-time polymerase chain reaction (RT-PCR). Results: DOX obviously demonstrated cytotoxic and anti-metastatic activities against A549 cells. Expression of gene-associated with both activities was potentiated by RES and RES analogues. Oxy-RES showed highest capability to potentiate DOX effects. DHoxy-RES showed nearly no effect to DOX activities. Conclusions: These results provided an important basis of DOX combination with RES analogues, especially Oxy-RES, for better therapeutic effect. Further studies in human should be performed on exploring combination of DOX and Oxy-RES.